Target intelligence / Profile preview

Mitochondrial dynamics pathway

Molecular classification
Other (Pathway/process involving: GTPase—specifically Dynamin-family proteins; Enzyme; Adaptors; multiple protein complexes)
01

Overview

Mitochondrial dynamics refers to the regulated processes of fission (division) and fusion (joining) of mitochondria, as well as their transport and turnover (mitophagy), which are critical for mitochondrial function, cellular energy production, quality control, and cell fate. These processes are orchestrated by key GTPase proteins (DRP1, MFN1, MFN2, OPA1) and their adaptors, whose activity is tightly controlled by cellular signaling and whose dysfunction is implicated in a wide range of human diseases including cancer, neurodegeneration, and metabolic syndrome[1][2][3][4][5][7][8]. While several components of mitochondrial dynamics present promising drug targets, the pathway itself is a system-level process and not a singular molecular entity.

Other names
Mitochondrial fusion-fission pathwayMitochondrial dynamicsMitochondrial quality control pathway
02

Mechanism of action

Inhibition of GTPase activity of fusion/fission proteins (e.g., DRP1, OPA1) Modulation of mitochondrial oxidative phosphorylation Scavenging of mitochondrial reactive oxygen species (ROS) Promotion of mitochondrial biogenesis (e.g., via PGC-1α activation) Modulation of mitochondrial quality control and apoptotic signaling

03

Biological functions

Cell cycleApoptosisSignal transductionCellular energy productionCell proliferationCell deathMitochondrial quality controlImmune response (modulates immune cell function)
04

Disease associations

CancerNeurodegenerative disease (e.g., Alzheimer’s, Parkinson’s)Cardiovascular diseaseMetabolic syndromeInflammationGenetic mitochondrial diseases
05

Safety considerations

Potential disruption of energy metabolismInduction of apoptosis/necrosis in healthy cellsOff-target effects due to central roles in cellular homeostasisMitochondrial inhibitor-related toxicity (e.g., hepatotoxicity)
06

Interacting drugs

MYLS22 (OPA1 inhibitor)

5 more in the full profile.

07

Biomarkers

Levels/activity of core proteins (DRP1, OPA1, MFN1/2)Mitochondrial morphology (fragmentation vs tubular networks)Cellular ROS levelsExpression of PGC-1α

Beyond the preview

Go deeper on Mitochondrial dynamics pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial dynamics pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call